Acadia Pharmaceuticals | ACAD - Cash And Equivalent


Acadia Pharmaceuticals reported $847.02M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 847.02M 85.02M Sep/2025
ALKERMES USD 616.45M 95.25M Sep/2025
Alnylam Pharmaceuticals USD 1.49B 376.56M Sep/2025
Biogen USD 3.86B 1.1B Sep/2025
BioMarin Pharmaceutical USD 1.25B 36.29M Sep/2025
Bristol-Myers Squibb USD 15.73B 3.13B Sep/2025
Corcept Therapeutics USD 125.14M 22.39M Sep/2025
Cytokinetics USD 225.47M 150.53M Sep/2025
Eisai JPY 285.38B 19.82B Jun/2025
Eli Lilly USD 9.79B 6.42B Sep/2025
Incyte USD 2.93B 508.08M Sep/2025
J&J USD 18.23B 10.35B Sep/2025
Moderna USD 1.13B 147M Sep/2025
Neurocrine Biosciences USD 340.2M 76.2M Sep/2025
Pfizer USD 1.34B 295M Sep/2025
Prothena USD 330.84M 40.6M Sep/2025
PTC Therapeutics USD 672.62M 344.77M Sep/2025
Sarepta Therapeutics USD 613.08M 102.48M Sep/2025
Ultragenyx Pharmaceutical USD 202.51M 36.4M Sep/2025
Vertex Pharmaceuticals USD 6.29B 95.8M Sep/2025